AR036593A1 - Uso de gch y hl en la hiperestimulacion ovarica controlada - Google Patents

Uso de gch y hl en la hiperestimulacion ovarica controlada

Info

Publication number
AR036593A1
AR036593A1 ARP020103457A ARP020103457A AR036593A1 AR 036593 A1 AR036593 A1 AR 036593A1 AR P020103457 A ARP020103457 A AR P020103457A AR P020103457 A ARP020103457 A AR P020103457A AR 036593 A1 AR036593 A1 AR 036593A1
Authority
AR
Argentina
Prior art keywords
gch
hyperestimulation
ovaric
controlled
rates
Prior art date
Application number
ARP020103457A
Other languages
English (en)
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8182262&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR036593(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of AR036593A1 publication Critical patent/AR036593A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/11—Gonadotropin; related peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/13—Luteinizing hormone-releasing hormone; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Reproductive Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Proporciona un protocolo que conduce a la tasas mejoradas de implantación de embriones y/o a la disminución de las tasas de abortos espontáneos, en el que se administra GCh o HL, o un bioanálogo de las mismas, durante la fase folicular.
ARP020103457A 2001-09-12 2002-09-12 Uso de gch y hl en la hiperestimulacion ovarica controlada AR036593A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01307758 2001-09-12

Publications (1)

Publication Number Publication Date
AR036593A1 true AR036593A1 (es) 2004-09-22

Family

ID=8182262

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020103457A AR036593A1 (es) 2001-09-12 2002-09-12 Uso de gch y hl en la hiperestimulacion ovarica controlada

Country Status (27)

Country Link
US (1) US7402558B2 (es)
EP (1) EP1425033B1 (es)
JP (1) JP2005501919A (es)
KR (1) KR20040032952A (es)
CN (1) CN100376289C (es)
AR (1) AR036593A1 (es)
AT (1) ATE489964T1 (es)
BR (1) BR0212447A (es)
CA (1) CA2457851A1 (es)
CY (1) CY1110991T1 (es)
DE (1) DE60238490D1 (es)
DK (1) DK1425033T3 (es)
EA (1) EA009279B1 (es)
ES (1) ES2356895T3 (es)
HK (1) HK1067865A1 (es)
HR (1) HRP20040086A2 (es)
IL (1) IL160782A0 (es)
ME (1) MEP38708A (es)
MX (1) MXPA04002257A (es)
NO (1) NO327153B1 (es)
PL (1) PL369021A1 (es)
PT (1) PT1425033E (es)
SI (1) SI1425033T1 (es)
UA (1) UA82052C2 (es)
WO (1) WO2003022303A2 (es)
YU (1) YU21104A (es)
ZA (1) ZA200400781B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040248784A1 (en) 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
GB0723882D0 (en) * 2007-12-07 2008-01-23 Univ Leicester Methods for the detection of a threatened miscarriage
EP2734239A2 (en) 2011-07-18 2014-05-28 Arts Biologics A/S Long acting luteinizing hormone (lh) compound
US20160024181A1 (en) 2013-03-13 2016-01-28 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
ES2716862T3 (es) * 2014-12-22 2019-06-17 Ferring Bv Terapia con antagonistas del receptor de oxitocina en la fase lútea para la implantación y embarazo en mujeres que se someten a tecnologías de reproducción asistida
SG11201706693QA (en) * 2015-02-26 2017-09-28 Ferring Bv Methods of treating infertility
US11185569B2 (en) * 2016-05-04 2021-11-30 University Of Cincinnati ActRIIB:Fc to treat infertility in females
MX2021004383A (es) * 2018-10-17 2021-06-04 Ferring Bv Composiciones y metodos para la estimulacion ovarica controlada.
CN110041436A (zh) * 2019-04-28 2019-07-23 广州威生医药科技有限公司 长效重组fsh融合蛋白在母猪批次化生产中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4589402A (en) 1984-07-26 1986-05-20 Serono Laboratories, Inc. Method of in vitro fertilization
US5705478A (en) * 1989-02-21 1998-01-06 Washington University Covalently linked β subunits of the glycoprotein hormones as antagonists
FR2744367B1 (fr) * 1996-02-02 1999-07-09 Emperaire Jean Claude Medicaments pour le declenchement de l'ovulation
DE69831241T2 (de) * 1997-06-20 2006-03-23 Akzo Nobel N.V. Gonadotropin freisetzendes Hormon Antagonist
ZA987497B (en) * 1997-09-08 1999-02-23 Akzo Nobel Nv Expression of gonadotropins in dictyostelium
US6090848A (en) * 1997-12-01 2000-07-18 Sigma-Tau Healthscience S.P.A. Compositions and methods for increasing the concentration and/or motility of spermatozoa in humans
ES2258445T3 (es) * 1999-02-24 2006-09-01 Novo Nordisk A/S Metodo in vitro para la sincronizacion de la maduracion de ovocitos.
EP1176976B2 (en) * 1999-05-07 2015-10-21 Laboratoires Serono SA Use of lh administered in mid- or late-follicular phase for the treatment of anovulatory women
RS50805B (sr) * 2000-01-27 2010-08-31 Laboratoires Serono Sa. Upotreba fsh za lečenje neplodnosti
US6953774B2 (en) * 2000-08-11 2005-10-11 Applied Research Systems Ars Holding N.V. Methods of inducing ovulation

Also Published As

Publication number Publication date
UA82052C2 (uk) 2008-03-11
NO327153B1 (no) 2009-05-04
EP1425033B1 (en) 2010-12-01
SI1425033T1 (sl) 2011-01-31
CN1553810A (zh) 2004-12-08
IL160782A0 (en) 2004-08-31
CN100376289C (zh) 2008-03-26
BR0212447A (pt) 2004-08-17
EP1425033A2 (en) 2004-06-09
ATE489964T1 (de) 2010-12-15
DE60238490D1 (de) 2011-01-13
US20050020489A1 (en) 2005-01-27
ZA200400781B (en) 2005-04-26
ES2356895T3 (es) 2011-04-14
JP2005501919A (ja) 2005-01-20
WO2003022303A2 (en) 2003-03-20
YU21104A (sh) 2006-08-17
NO20040962L (no) 2004-03-05
KR20040032952A (ko) 2004-04-17
MXPA04002257A (es) 2004-07-23
US7402558B2 (en) 2008-07-22
HK1067865A1 (en) 2005-04-22
CA2457851A1 (en) 2003-03-20
CY1110991T1 (el) 2015-06-11
EA009279B1 (ru) 2007-12-28
HRP20040086A2 (en) 2004-12-31
WO2003022303A3 (en) 2003-12-18
DK1425033T3 (da) 2011-01-10
PL369021A1 (en) 2005-04-18
EA200400426A1 (ru) 2004-08-26
MEP38708A (en) 2011-02-10
PT1425033E (pt) 2010-12-29

Similar Documents

Publication Publication Date Title
SE0100901D0 (sv) New composition
MY127290A (en) New use of flibanserin
CO5231161A1 (es) 4-aminopicolinatos y su uso como herbicidas
DK1283700T3 (da) Farmaceutiske sustained release-præparater til parenteral administration af biologisk aktive hydrofile forbindelser
SG148031A1 (en) Use of cci-779 as an antineoplastic agent
DE60029186D1 (de) Keramischer Schaumkörper
AU3831301A (en) Method for treating ocular pain
MXPA03007140A (es) Derivados de carbolina.
AR030829A1 (es) Una formulacion de vacuna, procedimiento para la produccion de la misma, uso de dicha preparacion y un estuche para su administracion via intranasal
ATE462424T1 (de) Therapeutische anwendung von zerstäubtem s- nitrosoglutathion bei zystischer fibrose
YU7804A (sh) Stabilni polimorf flibanserina,postupak za njegovo dobijanje u industrijskim razmerama i njegova primena za pripremanje lekova
MXPA02012076A (es) Compuestos quimicos.
ATE457132T1 (de) Aromakonzentrate
MXPA02012659A (es) Derivados de pirazindiona condensados.
AR036593A1 (es) Uso de gch y hl en la hiperestimulacion ovarica controlada
MXPA03010655A (es) Gel oft??lmico de pirenzepina.
ES2160410T3 (es) Preparados de complejos de protrombina inmunotolerantes.
MXPA04002256A (es) Uso de gonadotropina corionica humana (gch) en hiperestimulacion ovarica controlada.
DK1272220T3 (da) Formulering til forebyggelse af kardiovaskulær sygdom
DK1274414T3 (da) Nasal administration af Metocloropramid til behandling af Gastroparese
MXPA03001081A (es) Medicamento anti-inflamatorio.
DE60120120D1 (de) Beutelformzusammensetzungen
NO20030919L (no) Trombomodulinanaloger til anvendelse ved rekonvalesens etter ryggmargsskade
WO2002024181A3 (en) The use of melatonin for induction of general anesthesia
TR200302134T4 (tr) 2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı.

Legal Events

Date Code Title Description
FB Suspension of granting procedure